ATR and cancer: Because SLFN11-deficient cancer cells rely on the ATR pathway to modulate their DNA replication and damage repair processes in response to replication stress, the combination of ATR inhibitors with DDAs is selectively active in SLFN11-negative cancer cells47,76.